| http://www.w3.org/ns/prov#value | - Now, researchers at Memorial Sloan-Kettering Cancer Center report in Cell today that anti-CD20 antibodies, such as rituximab, might be a viable delivery system for at least one tumor suppressor protein that appears to drive follicular lymphoma.
|
